肥胖是一种慢性进展性疾病，全球已有超过10亿人受到影响。它显著增加发生严重心血管事件的风险，如心力衰竭、冠心病和中风。同 时，肥胖还会导致寿命大幅缩短——男性缩短9.1年，女性缩短7.7年。尽管治疗至关重要，但许多减重方法无法长期奏效。 整理 | GLP1减重宝典内容团队 美国心脏病学会（ACC）近日发布《简明临床指南》（CCG），旨在为临床医生提供用药管理体重的指导，特别是在减重可能带来心 血管益处的患者中。 近年来的新型药物，特别是司美格鲁肽和替尔泊肽，相较单纯的生活方式干预，不仅在减重方面更为有效，也能降低心血管疾病 （CVD）的整体风险，而且风险低于手术类治疗方法。此前的指南通常建议先进行生活方式干预，再考虑药物治疗；而此次发布的新 指南则建议将药物作为符合条件患者的优先治疗选项之一。 "患者不应在'尝试生活方式改变失败'之后才被允许使用药物治疗，当然，生活方式干预仍应作为治疗的一部分。"该指南主席、Atrium Health Wake Forest Baptist医学中心的心脏科医生奥利维亚·吉尔伯特博士表示。 本次指南明确了临床医生将药物治疗纳入心血管管理决策过程中的关键要点： 适应证与治疗依据 ...

Core Viewpoint - The recent phase II clinical trial results from Eli Lilly demonstrate significant efficacy in weight management when combining Bimagrumab with Semaglutide (Wegovy), with participants experiencing an average weight loss of 22.1% over 48 weeks, compared to 15.7% with Semaglutide alone [2][4]. Group 1 - The combination therapy shows a synergistic effect, leading to greater weight loss and preservation of lean body mass, which is particularly important for populations at risk of sarcopenia [4]. - Bimagrumab, an antibody targeting activin receptor type II, helps protect muscle quality during weight loss, addressing a common issue with GLP-1 medications that can lead to muscle loss [2][4]. - The research highlights the need for a multidisciplinary approach to obesity treatment, integrating medication, lifestyle changes, and psychological support [5]. Group 2 - Eli Lilly is also advancing clinical trials for Bimagrumab in combination with Zepbound, a dual-target GLP-1/GIP agonist, expanding treatment options for patients [5]. - The successful results of the phase II trial mark a significant advancement in obesity treatment, potentially leading to a new paradigm in weight management strategies [5]. - This "dual-target, dual-effect" treatment model may become a key breakthrough in personalized and refined weight loss therapies, benefiting millions globally [5].

Core Viewpoint - The recent STEP UP trial demonstrated that high-dose Wegovy® (semaglutide 7.2 mg) significantly reduces weight in non-diabetic obese individuals, with an average weight loss of 21%, and one-third of participants losing over 25% of their body weight [2][9]. Group 1: Trial Results - The STEP UP trial showed that semaglutide 7.2 mg resulted in a 20.7% average weight reduction compared to 17.5% for the 2.4 mg dose and 2.4% for the placebo group [2][8]. - In the 7.2 mg group, 93.2% of participants achieved at least a 5% weight loss, while 92.5% in the 2.4 mg group and only 35.7% in the placebo group reached this milestone [2][8]. - The trial included 1,407 adults with a BMI ≥30 kg/m² and was designed to assess the efficacy and safety of semaglutide 7.2 mg over 72 weeks [9]. Group 2: Safety and Tolerability - The 7.2 mg dose of semaglutide exhibited good tolerability consistent with previous studies, with gastrointestinal reactions being the most common side effects, typically mild to moderate [5][6]. - The discontinuation rate due to gastrointestinal side effects was low: 3.3% in the 7.2 mg group, 2.0% in the 2.4 mg group, and 0% in the placebo group [6]. Group 3: Future Developments - Novo Nordisk plans to submit an updated label application to the EU in the second half of 2025, followed by submissions in other markets where Wegovy® is approved [7]. - The company is also developing an oral formulation of Wegovy®, which, upon FDA approval, could become the first oral GLP-1 medication to achieve double-digit weight loss [3].

Core Viewpoint - The article emphasizes the importance of scientific weight management and the dangers of seeking quick fixes through medications or surgeries, advocating for lifestyle changes and professional guidance instead [5][10][15]. Group 1: Weight Management Trends - The topic of weight management has gained significant public attention, reflecting a growing awareness of healthy lifestyles [5]. - There is a notable increase in the number of patients seeking medical support for weight management, with a reported rise in outpatient visits from 10,000 in 2015 to 60,000 in 2024 [15][16]. Group 2: Expert Opinions on Weight Loss Methods - Experts warn against the pursuit of rapid weight loss methods, stating that relying solely on medications without lifestyle changes can lead to weight regain and health risks [6][7]. - Medical weight loss strategies include nutritional intervention, medication, and surgical options, with a strong emphasis on the necessity of professional guidance [10][11]. Group 3: Importance of Exercise - Regular physical activity is highlighted as a crucial component of effective weight management, with recommendations for daily walking of 1 to 1.5 hours [11][13]. - Exercise not only aids in fat metabolism but also helps prevent muscle loss and maintains a healthy metabolic rate [11][13]. Group 4: Policy and Industry Outlook - The Chinese government is actively promoting weight management through initiatives like the "Weight Management Year" campaign, aiming to enhance public awareness and skills in weight management [15][16]. - New guidelines and policies are being established to standardize obesity treatment and improve the overall healthcare framework for weight management [15][16].

Core Viewpoint - Novo Nordisk's experimental weight loss drug Amycretin shows significant efficacy in early clinical trials, with weight loss of up to 24% in overweight and obese adults, laying the groundwork for a large Phase III trial planned for next year [2][6]. Group 1: Drug Efficacy and Mechanism - Amycretin is administered either weekly via injection or daily orally, with gastrointestinal side effects similar to other recently launched weight loss drugs [3]. - The drug operates through a dual mechanism, mimicking the gut hormone GLP-1 and activating the appetite-suppressing hormone amylin, which may contribute to its enhanced weight loss effects [6]. - In injection trials, patients receiving 20 mg of Amycretin weekly lost an average of 22% of their weight over 36 weeks, while those on a 60 mg dose lost 24.3% [7]. Group 2: Comparative Analysis and Future Research - In oral trials, participants increased their dosage from 3 mg to a maximum of 100 mg over 12 weeks, with those on 50 mg losing an average of 10.4% and those on the highest dose losing 13.1% [7]. - The weight loss trend did not plateau at the end of the trial, suggesting that longer-term treatment may yield greater weight loss [7]. - Experts emphasize the need for direct comparative studies between GLP-1 drugs like semaglutide and new drugs like Amycretin to clarify their relative value and positioning in obesity treatment [7].

整理 | GLP1减重宝典内容团队 REDEFINE 1和REDEFINE 2的研究数据显示，卡格利肽（cagrilintide）2.4 mg与司美格鲁肽（semaglutide）2.4 mg联合使用（即 CagriSema）所带来的减重效果，已处于当前肥胖治疗手段中的最高水平之一。 这项研究成果在近日举办的第85届美国糖尿病协会（ADA 2025）科学年会上公布，并同步发表在《新英格兰医学杂志》 。此次研究是 由诺和诺德资助进行的，目前为止是对CagriSema这一疗法最深入的评估。该疗法结合了双重作用的卡格利肽（一种兼具胰淀素和降钙 素受体激动剂功能）与GLP-1受体激动剂司美格鲁肽。 "在REDEFINE 1试验中，参与者在个体化剂量调整的前提下仍实现了显著且临床意义明确的体重下降，"诺和诺德研发执行副总裁 Martin Holst Lange表示，"在REDEFINE 1和2中，不良事件导致的停药率也维持在低水平。这些数据增强了我们对CagriSema的信心， 我们也将继续通过REDEFINE系列研究探索其潜力。" ▍ REDEFINE 1 REDEFINE 1是一项为期68周的3a期双盲临床试验，共 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 2025年3月，国家卫生健康委员会主任雷海潮正式宣布启动"体重管理年"三年专项行动，推动各级医疗机构设立专业体重管理门诊。为什么国 家如此重视体重管理？目前我国成人超重率已达34.3%，肥胖率高达16.4%，也就是说，超过一半的成年人正面临超重或肥胖困扰，减重已成为 提升全民健康水平的关键一环。 对于各类诊所来说，开设减重门诊不仅是积极响应国家政策，更是增强患者粘性、拓展慢性病管理服务的绝佳机会。小管家今天结合多家医疗 机构的实战经验，从前期筹备到后续运营，带你全流程解锁诊所"减重门诊"的打造秘籍。 ▍为什么诊所要开设减重门诊？ 1. 患者需求激增 目前，全国超重和肥胖人数已突破6亿，肥胖与糖尿病、高血压等慢性疾病密切相关。科学数据显示，及早干预可降低80%的糖尿病发病风险。 减重管理需要长期跟进，患者粘性强，有助于提升复诊率和口碑传播。例如，南京新街口社区卫生服务中心通过微信群管理患者，显著提升了 患者的依从性。 2. 政策红利加持 ▍四步落地：减重 ...

Core Viewpoint - WeightWatchers has filed for a "pre-packaged" restructuring under Chapter 11 of the U.S. Bankruptcy Code, aiming to reduce debt by up to $1.15 billion, marking a significant shift towards medical weight loss solutions centered around GLP-1 drugs [1][2]. Financial Restructuring Framework - The restructuring plan is designed to alleviate debt pressure and provide strategic flexibility, reducing the company's net leverage ratio from over 8 times to approximately 2.5 times EBITDA [1]. - The plan includes annual interest savings of about $50 million, significantly improving profit margins [1]. - The company will issue $465 million in secured debt maturing in 2030 to extend repayment timelines [1]. - Existing debt will be converted into new securities, with creditors holding 91% of the restructured company, while original shareholders may retain about 9% equity, facing potential dilution [1]. Clinical Shift: Focus on GLP-1 Weight Loss Drugs - The strategic pivot emphasizes an increase in telehealth services, with a reported 57% year-over-year growth in this segment for Q1 2025, driven by the acquisition of telehealth startup Sequence for $106 million [2][3]. - WeightWatchers aims to become a "behavioral guidance layer" within the GLP-1 ecosystem, involving drugs like Wegovy, Ozempic, and Mounjaro [3]. Business Continuity During Restructuring - WeightWatchers assures that its services will remain uninterrupted during the restructuring process, continuing to serve over 3 million members globally [6]. - All in-person activities and online platforms will operate as usual, with clinical service users maintaining access to telehealth [7]. Future Projections - Analysts outline three potential future scenarios for the company post-restructuring: - **Optimistic Scenario**: Clinical users reach 1 million, stable traditional services, projected revenue of $1.3 billion by 2028, EBITDA margin of 18%, and a market value nearing $4 billion [10]. - **Neutral Scenario**: Clinical users grow to 600,000, traditional business declines by 5% annually, resulting in $900 million revenue, 14% margin, and an estimated valuation of $1.8 billion [11]. - **Pessimistic Scenario**: Clinical users stagnate at 300,000, traditional business continues to deteriorate, leading to $600 million revenue, 10% margin, and a significant drop in enterprise value [12]. Strategic Variables for Future Development - Future growth may depend on partnerships with pharmaceutical companies, insurance coverage for GLP-1 drugs, transformation of physical locations into health centers, development of AI-guided tools, and integration of dietary products aligned with GLP-1 medication [12]. Investment Opportunities Perspective - For investors, WeightWatchers presents multiple strategic windows: - **Short-term (0-6 months)**: Common stock may offer speculative value, while bond trading provides defensive characteristics and potential returns [14]. - **Mid-term (6-24 months)**: Monitoring clinical user growth with a target of exceeding 500,000 users by the end of 2026 [14]. - **Long-term (2+ years)**: The company's ability to achieve sustainable profitability through a drug-supported platform will determine its ultimate valuation [14].

Core Viewpoint - The article emphasizes the importance of weight management as a national health strategy, highlighting the rising obesity rates in China and the associated health risks, urging individuals to take proactive steps towards maintaining a healthy weight [3][10][11]. Group 1: National Health Strategy - The "Weight Management Year" initiative is part of the "Healthy China 2030" strategy, aiming to combat the obesity crisis and promote public health [3][10]. - By 2030, it is projected that the overweight and obesity rates among adults and children in China will reach 70.5% and 31.8% respectively if no action is taken [10][11]. Group 2: Health Risks Associated with Obesity - Chronic diseases such as hypertension, diabetes, cardiovascular diseases, and even cancer are linked to uncontrolled weight, making obesity a significant health threat [3][7]. - The article warns that the increase in weight is associated with various health issues, including fatty liver, metabolic disorders, and joint damage [7]. Group 3: Recommended Actions for Individuals - Individuals are encouraged to make small dietary adjustments, such as reducing oil and salt intake and increasing physical activity by walking an extra 1,000 steps daily [7]. - The article suggests practical dietary changes, including substituting white rice with whole grains, ensuring a nutritious breakfast, and avoiding high-energy foods [11]. Group 4: Community and Professional Support - The initiative calls for community participation in weight management and offers resources such as professional nutritionists and health coaches to help individuals create personalized dietary plans [7][10].

整理 | GLP1减重宝典内容团队 在2022年国际糖尿病联盟（IDF）大会上，首次以墙报形式展示了PIONEER 11和PIONEER 12研究的结果。这两项研究以中国人群为 主，为司美格鲁肽片（商品名：诺和忻）在中国的获批提供了重要支持。该药物的治疗剂量为7mg或14mg，适用于在饮食和运动控制 不足的基础上，作为单药或与二甲双胍和/或磺脲类药物联合治疗的成人2型糖尿病（T2DM）患者。 与欧美人群不同，中国的2型糖尿病患者通常在较年轻时就被诊断，且BMI较低，这可能影响药物的治疗效果，因此中国研究是必要 的。 在中国人群中，司美格鲁肽片的疗效和安全性数据相对较少，PIONEER 11和12研究则为该领域提供了重要的临床数据。 PIONEER系列的全球3期临床试验比较了司美格鲁肽片与活性对照药物及安慰剂在降糖效果和安全性上的差异，以及体重的减轻，结果 显示，司美格鲁肽片能够持续改善血糖控制以及减重，且效果优于活性对照药物和安慰剂。 ▍PIONEER 11 单药治疗 PIONEER 11研究在饮食和运动控制不佳的中国2型糖尿病患者中，评估了司美格鲁肽片单药治疗的有效性与安全性。研究结果显示， 中国 人群的临 ...